Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III trial of NM57S/NC08 versus HRIG with rabies vaccine in adults with category III rabies exposure
CTR20251420Phase 3Active
- Sponsor
- North China Pharmaceutical Group Corporation
- Start
- Jul 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of NM57S + NC08 in rabies, sponsored by North China Pharmaceutical Group Corporation. Started Jul 2025; status: active.
02
Drugs
NM57S + NC08
03
Conditions
rabies
Beyond the preview
Go deeper on CTR20251420.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20251420.